Early Improvement in the First 2 Weeks as a Predictor of Treatment Outcome in Patients With Major Depressive Disorder: A Meta-Analysis Including 6562 Patients
The DOI matches its Crossref record.
Abstract
OBJECTIVE: New evidence indicates that treatment response can be predicted with high sensitivity after 2 weeks of treatment. Here, we assess whether early improvement with antidepressant treatment predicts treatment outcome in patients with major depressive disorder (MDD). DATA SOURCES: Forty-one clinical trials comparing mirtazapine with active comparators or placebo in inpatients and outpatients (all-treated population, N = 6907; intent-to-treat population, N = 6562) with MDD (DSM-III-R or DSM-IV Criteria) were examined for early improvement (>or= 20% score reduction from baseline on the 17-item Hamilton Rating Scale for Depression [HAM-D-17] within 2 weeks of treatment) and its relationship to treatment outcome. STUDY SELECTION: Data were obtained from a systematic search of single- or double-blind clinical trials (clinical trials database, Organon, a part of Schering-Plough Corporation, Oss, The Netherlands). All included trials (a total of 41) employed antidepressant treatment for more than 4 weeks and a maximum of 8 weeks. The studies ranged from March 1982 to December 2003. Trials were excluded if there were no HAM-D-17 ratings available, no diagnosis of MDD, or if the study was not blinded. Trials were also excluded if HAM-D-17 assessments were not available at week 2, week 4, and at least once beyond week 4. DATA SYNTHESIS: Early improvement predicted stable response and stable remission with high sensitivity (>or= 81% and >or= 87%, respectively). Studies utilizing rapid titration vs. slow titration of mirtazapine demonstrated improved sensitivity for stable responders (98%, [95% CI = 93% to 100%] vs. 91% [95% CI = 89% to 93%]) and stable remitters (100%, [95% CI = 92% to 100%] vs. 93% [95% CI = 91% to 95%]). Negative predictive values for stable responders and stable remitters were much higher (range = 82%-100%) than positive predictive values (range = 19%-60%). CONCLUSIONS: These results indicate that early improvement with antidepressant medication can predict subsequent treatment outcome with high sensitivity in patients with major depressive disorder. The high negative predictive values indicate little chance of stable response or stable remission in the absence of improvement within 2 weeks. A lack of improvement during the first 2 weeks of therapy may indicate that changes in depression management should be considered earlier than conventionally thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although 60% of persons who achieved remission in the STAR * D trial with level 1 treatment did so after week 6 of treatment”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [168]
In the citing paper
“The adequate duration of an antidepres sant trial is generally considered to be 4- 6 weeks at optimal dosing”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [168]
In the citing paper
“the partial responses at 2 weeks have, nonetheless, been shown to be strongly correlated with subsequent remission [19,51].”
Citations
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
“For the treatment with antidepressant, antipsychotic or mood stabilizing drugs, there is good evidence that clinical non-improvement at week 2 is highly predictive for later treatment failure [196, 239, 615, 696, 1130, 1131, 1162].”
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“…within the fi rst 14 days of treatment (Nierenberg et al. 2000; Szegedi et al. 2003; Katz et al. 2004; Posternak and Zimmerman 2005; Papakostas et al. 2006; Taylor et al. 2006; Stassen et al. 2007; Henkel et al. 2009; Hennings et al. 2009; Szegedi et al. 2009; Tadic et al. 2010b; Uher et al. 2010).”
BackgroundInfluentialSforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
“In terms of ‘minimum duration’, some studies have shown that, while two weeks can be enough to observe an initial response, a stable response/remission is usually detectable after four weeks [37, 38].”
BackgroundLundberg, J., Cars, T., Lööv, S.-Å., Söderling, J., Sundström, J., Tiihonen, J., Leval, A., Gannedahl, A., Björkholm, C., Själin, M., et al. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.3860 · Cited by 166
“7% women; median [IQR] age, 42 years [30-56]).”
Treatment-Resistant Depression in Primary Care across Canada
Rizvi, S. J., Grima, E., Tan, M., Rotzinger, S., Lin, P., McIntyre, R. S., & Kennedy, S. H. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900702 · Cited by 144
Annual Research Review: Defining and treating pediatric treatment‐resistant depression
Dwyer, J. B., Stringaris, A., Brent, D. A., & Bloch, M. H. (2020) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13202 · Cited by 148
“Previous trials in adult depression have also strongly associated early SSRI response with improved treatment response (Szegedi et al., 2009).”
ResultBiernacka, J. M., Sangkuhl, K., Jenkins, G., Whaley, R. M., Barman, P., Batzler, A., Altman, R. B., Arolt, V, Brockmöller, J., Chen, C. H., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.47 · Cited by 140
Phillips, J. L., Batten, L. A., Tremblay, P., Aldosary, F., & Blier, P. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv037 · Cited by 144
“At study visits (once every 2 weeks), patients were assessed by administration of the MADRS if an approximate 20% symptom improvement was not detected (Szegedi et al., 2009), an increase in doses (if tolerated), a change in medication, or an augmentation strategy was implemented.”
MethodPark, S., & Kim, J. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06525-0 · Cited by 189
“Its eventual remission rate with early improvement reaches over 80% [10].”
BackgroundTrajectories of change in depression severity during treatment with antidepressants
Uher, R., Muthén, B., Souery, D., Mors, O., Jaracz, J., Placentino, A., Petrovic, A., Zobel, A., Henigsberg, N., Rietschel, M., et al. (2010) · Psychological Medicine · doi:10.1017/s0033291709991528 · Cited by 128
“2006) and have shown that early improvement predicts stable long-term improvement (Szegedi et al. 2003 ; Papakostas et al. 2007; Szegedi et al. 2009).”
BackgroundResultGeschwind, N., Nicolson, N. A., Peeters, F., van Os, J., Barge-Schaapveld, D., & Wichers, M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.11.004 · Cited by 119
Gueorguieva, R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.132 · Cited by 115
Sackeim, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., Demitrack, M. A., George, M. S., Prudic, J., Thase, M. E., & Rush, A. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.021 · Cited by 109
“There is substantial evidence that early clinical improvement with antidepressant pharmacotherapy has positive predictive value regarding ultimate response or remission, and that early lack of symptomatic improvement has negative predictive value (Leuchter et al., 2009; Nierenberg et al., 1995; Papakostas et al., 2006…”
BackgroundSelf-citationOluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx081 · Cited by 104
“Baseline and weekly assessments of both depressive symptoms and functioning are therefore recommended (Szegedi et al., 2009; Lam et al., 2011).”
BackgroundPredicting relapse after antidepressant withdrawal – a systematic review
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M. (2017) · Psychological Medicine · doi:10.1017/s0033291716002580 · Cited by 93
Kudlow, P., McIntyre, R., & Lam, R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0171-5 · Cited by 84
“While the benefits of switching antidepressant medications after a failed trial have been investigated in many openlabel studies and RCTs [20–22], only three studies have investigated the timing of switch strategies for antidepressant non-responders (Table 2).”
InfluentialJaworska, N., de la Salle, S., Ibrahim, M.-H., Blier, P., & Knott, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00768 · Cited by 99
“A meta-analysis found that a 20% reduction on the Hamilton Rating Scale for Depression (HAMD-17) within 2 weeks post-treatment initiation was predictive of later response and remission with a high sensitivity [81–87%; (101)].”
Trajectories of depression and anxiety symptom change during psychological therapy
Saunders, R., Buckman, J. E. J., Cape, J., Fearon, P., Leibowitz, J., & Pilling, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.043 · Cited by 99
Karaiskos, D., Tzavellas, E., Spengos, K., Vassilopoulou, S., & Paparrigopoulos, T. (2012) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.11110325 · Cited by 97
Belzeaux, R., Formisano-Tréziny, C., Loundou, A., Boyer, L., Gabert, J., Samuelian, J.-C., Féron, F., Naudin, J., & Ibrahim, E. C. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.04.011 · Cited by 95
Bareš, M., Brunovský, M., Novák, T., Kopeček, M., Stopková, P., Šóš, P., Krajča, V., & Höschl, C. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.03.007 · Cited by 100
Huang, M.-L., Luo, B.-Y., Hu, J.-B., Wang, S.-S., Zhou, W.-H., Wei, N., Hu, S.-H., & Xu, Y. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867411433216 · Cited by 90
“More recently, this view has been challenged by those who believe that an earlier onset of antidepressants (i.e., before 2 weeks) is highly prevalent and can be highly predictive of later outcomes (Henkel et al., 2009; Szegedi et al., 2009; van Calker et al., 2009).”
BackgroundInfluentialA new paradigm for the prediction of antidepressant treatment response
Leuchter, A. F., Cook, I. A., Hunter, A. M., & Korb, A. S. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/afleuchter · Cited by 90
Onset, time course and trajectories of improvement with antidepressants
Lam, R. W. M. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.005 · Cited by 92
“A large (N=41 RCTs with 6562 patients) pooled analysis of mirtazapine, comparators and placebo also found that early improvement (Z20% reduction in HAMD) at 2 weeks predicted sustained response and remission at 6–8 weeks, but the negative predictive value was higher than the positive predictive value (Szegedi et al.,…”
BackgroundChen, E. Y., Cacioppo, J., Fettich, K., Gallop, R., McCloskey, M. S., Olino, T., & Zeffiro, T. A. (2017) · Psychological Medicine · doi:10.1017/s0033291716002543 · Cited by 83
“How can we use stepped care to improve the lives of clients for whom standard treatments are not fully effective? One of the few trans-diagnostic and treatment-agnostic predictors of outcome after a full treatment course is ‘early weak response’ or ‘rapid response’ after 2–8 treatment weeks (Crits-Christoph et al. 200…”
BackgroundInfluentialTreating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 84
“Incredulously, 6 decades after imipramine was introduced into psychiatry, the fundamental question as to what comprises a sufficient antidepressant trial duration remains a point of discussion/debate.(25,26) Available evidence indicates that changes in cognitive-emotional processing with antidepressants are apparent a…”
BackgroundShen, Y., Yao, J., Jiang, X., Zhang, L., Xu, L., Feng, R., Cai, L., Liu, J., Wang, J., & Chen, W. (2015) · Human Brain Mapping · doi:10.1002/hbm.22817 · Cited by 83
“Specifically, a meta-analysis including 6,562 patients with MDD shows that early improvement within the first 2 weeks of antidepressant treatment predicts stable response and remission with high negative predictive values [Szegedi et al., 2009].”
BackgroundClinical predictors of response and remission in inpatients with depressive syndromes
Riedel, M. J., Möller, H., Obermeier, M., Adli, M., Bauer, M., Kronmüller, K., Brieger, P., Laux, G., Bender, W., Heuser, I., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.007 · Cited by 95
“Later, Szegedi reported even higher sensitivity figures in his meta-analysis on 6907 patients (81% for response and 87% for remission) (Szegedi et al., 2009).”
BackgroundGougol, A., Zareh-Mohammadi, N., Raheb, S., Farokhnia, M., Salimi, S., Iranpour, N., Yekehtaz, H., & Akhondzadeh, S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115578160 · Cited by 77
Wagner, S., Engel, A., Engelmann, J., Herzog, D., Dreimüller, N., Müller, M. B., Tadić, A., & Lieb, K. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.07.003 · Cited by 73
Accelerating response to antidepressant treatment in depression: A review and clinical suggestions
Nakajima, S., Suzuki, T., Watanabe, K., Kashima, H., & Uchida, H. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.001 · Cited by 80
Peeters, F. P. M. L., Ruhe, H. G., Wichers, M., Abidi, L., Kaub, K., van der Lande, H. J., Spijker, J., Huibers, M. J. H., & Schene, A. H. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.08.019 · Cited by 72
“For example, the NICE guideline (www.nice.org. uk/guidance/qs8) states that a minimum period of 6–8 weeks is required to assess effectiveness, however other reports advocate earlier switching (after 2 weeks) when insufficient early response is achieved (Szegedi et al., 2009; Tadic et al., 2016).”
BackgroundDefault mode network deactivation during emotion processing predicts early antidepressant response
Spies, M., Kraus, C., Geissberger, N., Auer, B., Klöbl, M., Tik, M., Stürkat, I.-L., Hahn, A., Woletz, M., Pfabigan, D. M., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.265 · Cited by 68
Tadić, A., Wagner, S., Schlicht, K. F., Peetz, D., Borysenko, L., Dreimüller, N., Hiemke, C., & Lieb, K. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.011 · Cited by 82
“E.g., the largest meta-analysis in this field (Szegedi et al., 2009) showed that nonimprovement after two weeks of treatment is a highly specific predictor for final non-response (81–98% across the investigated studies) and non-remission (87–100%).”
Feffer, K., Lee, H. H., Mansouri, F., Giacobbe, P., Vila‐Rodriguez, F., Kennedy, S. H., Daskalakis, Z. J., Blumberger, D. M., & Downar, J. H. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.10.010 · Cited by 74
“In a meta-ana lysis cross 41 clinical trials enrolling 6562 patients, early improvement ( ≥20% symptom score reduction) in the first 2 weeks o f treatment was an accurate predictor of stable response and re mission[34].”
Dreimüller, N., Schlicht, K. F., Wagner, S., Peetz, D., Borysenko, L., Hiemke, C., Lieb, K., & Tadić, A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.017 · Cited by 75
“…sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of an early molecular change either as single marker or in combination with early symptom improvement for final response according to established methods (Szegedi et al., 2003, 2009; Tadi c et al., 2010).”
BackgroundMethodKemp, D. E., Ganocy, S. J., Brecher, M., Carlson, B. X., Edwards, S., Eudicone, J. M., Evoniuk, G., Jansen, W., Leon, A. C., Minkwitz, M., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.10.026 · Cited by 62
“In this bipolar cohort, early improvement predicted later response and remission with high sensitivity (75%/70%), a value lower than in unipolar depression where the sensitivity was found to be greater than 90% (Szegedi et al., 2009; Szegedi et al., 2003).”
BackgroundResultInfluentialSelf-citationKorb, A. S., Hunter, A. M., Cook, I. A., & Leuchter, A. F. (2011) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2010.12.007 · Cited by 59
“Conversely, the absence of early improvement during pharmacotherapy is associated with poor 8-week outcome (Nierenberg et al., 1995; Szegedi et al., 2009), although the lack of specificity of these changes limits the usefulness of this measure as a sole predictor (Leuchter et al., 2009b; Szegedi et…”
BackgroundAn update on antidepressant use in bipolar depression
Sidor, M. M., & MacQueen, G. M. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0323-6 · Cited by 57
“In a meta-analysis of 41 clinical trials comparing mirtazapine with active comparators or placebo in inpatients and outpatients, the negative predictive value of early non-response was >80 % [55].”
The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents
Fasipe, O. J. (2019) · IBRO Reports · doi:10.1016/j.ibror.2019.01.001 · Cited by 63
“Nefazodone and trazodone are the pioneer members of this class with potently strong 5-HT2 receptor antagonism/blockade (Szegedi et al., 2009; Reynolds et al., 2011).”
BackgroundDynamic Prediction of Treatment Response in Late-Life Depression
Joel, I., Begley, A. E., Mulsant, B. H., Lenze, E. J., Mazumdar, S., Dew, M. A., Blumberger, D., Butters, M., & Reynolds, C. F. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.07.002 · Cited by 55
Lieb, K., Dreimüller, N., Wagner, S., Schlicht, K., Falter, T., Neyazi, A., Müller-Engling, L., Bleich, S., Tadić, A., & Frieling, H. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00511 · Cited by 54
Zhao, Y., He, Z., Luo, W., Yu, Y., Chen, J., Cai, X., Gao, J., Li, L., Gao, Q. C., Chen, H., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.061 · Cited by 58
Möller, H.-J., Bitter, I., Bobes, J., Fountoulakis, K., Höschl, C., & Kasper, S. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.08.002 · Cited by 53
“Especially the insufficient response in the first 14 days of therapy with antidepressants seems to be of great prognostic importance for the further therapy course as regards response and remission [63,180].”
BackgroundDunlop, B. W., Li, T., Kornstein, S. G., Friedman, E. S., Rothschild, A. J., Pedersen, R., Ninan, P., Keller, M., & Trivedi, M. H. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.04.032 · Cited by 52
Trajectories of individual symptoms in remitters versus non-remitters with depression.
Sakurai, H., Uchida, H., Abe, T., Nakajima, S., Suzuki, T., Pollock, B., Sato, Y., & Mimura, M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.035 · Cited by 53
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 57
“An absence of any change (improvement less than 20%) during the first 2 weeks of treatment was even higher predictive for later clinical nonresponse [231, 409, 413, 420].”
Backgroundde Vries, Y. A., Roest, A. M., Bos, E. H., Burgerhof, J. G. M., van Loo, H. M., & de Jonge, P. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.122 · Cited by 50
“Participants with missing data for week 6 or week 12 outcomes were largely comparable to participants that did have valid data, but were less likely to show early improvement (Supplementary Table 8).”
InfluentialAnxious depression: Clinical features and treatment
Rao, S. D., & Zisook, S. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0065-2 · Cited by 52
Deardorff, W. J., & Grossberg, G. T. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.960842 · Cited by 49
“Onset of action is an important issue given that early improvement predicts a more stable response to treatment and greater rates of remission [72,73].”
BackgroundTadić, A., Wachtlin, D., Berger, T., Braus, D. F., van Calker, D., Dahmen, N., Dreimüller, N., Engel, A., Gorbulev, S., Helmreich, I., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.02.003 · Cited by 50
Mahlich, J., Tsukazawa, S., & Wiegand, F. (2018) · Drugs - Real World Outcomes · doi:10.1007/s40801-017-0126-5 · Cited by 49
Olgiati, P., Serretti, A., Souery, D., Dold, M., Kasper, S. F., Montgomery, S., Zohar, J., & Mendlewicz, J. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.004 · Cited by 57
Pei, C., Sun, Y., Zhu, J., Wang, X., Zhang, Y., Zhang, S., Yao, Z., & Lü, Q. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27029 · Cited by 49
“…improvement after the fi rst 2 weeks of antidepressant treatment can predict subsequent treatment outcome with high sensitivity in patients with MDD. 16,17 Assisted by early-stage response prediction, clinicians can decide to continue or change treatment earlier, thus decreasing morbidity and…”
BackgroundInfluentialGuidelines for the diagnosis and treatment of depressive disorders in China: The second edition
Feng, Y., Xiao, L., Wang, W., Ungvari, G. S., Ng, C. H., Wang, G., & Xiang, Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.104 · Cited by 51
Poirot, M. G., Ruhé, H. G., Mutsaerts, H. J. M. M., Maximov, I. I., Groote, I. R., Bjørnerud, A., Marquering, H. A., Reneman, L., & Caan, M. W. A. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230206 · Cited by 54
Kim, J.-M., Kim, S.-Y., Stewart, R. J., Yoo, J.-A., Bae, K., Jung, S.-W., Lee, M., Yim, H. W., & Jun, T. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.09.007 · Cited by 48
“Based on HAMD score changes, the remission and response rates by final follow-up were 35% and 54% in this study, also similar to previous studies reporting 18–38% remission rates and 39– 63% response rates (Henkel et al., 2009; Stassen et al., 1997; Szegedi et al., 2003, 2009).”
BackgroundMethodResultInfluentialLin, H.-S., & Lin, C.-H. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.105 · Cited by 45
Hou, Z., Kong, Y., He, X., Yin, Y., Zhang, Y., & Yuan, Y. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.026 · Cited by 46
Bennett, C. C. (2012) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2012.02.011 · Cited by 44
“For example, a patient suffering from Major Depression who was on citalopram 20 mg until 3 months prior to the start of treatment with a new provider may not represent a true baseline due to residual effects of the previous treatment [9,10].”
BackgroundKelley, M. E., Dunlop, B. W., Nemeroff, C. B., Lori, A., Carrillo-Roa, T., Binder, E. B., Kutner, M. H., Rivera, V. A., Craighead, W. E., & Mayberg, H. S. (2018) · Depression and Anxiety · doi:10.1002/da.22832 · Cited by 43
“Patients were randomized 1:1:1 to one of three possible phase 1 treatments over 12 weeks: (1) escitalopram (ESC): 10–20 mg/d, (2) duloxetine (DUL): 30–60 mg/d, or (3) CBT, 16 individual 1-hr sessions.”
BackgroundInfluentialPrediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive Disorder
Yan, D., Liu, J., Liao, M., Liu, B., Wu, S., Li, X., Li, H., Ou, W., Zhang, L., Li, Z., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.695272 · Cited by 46
Bareš, M., Novák, T., Kopeček, M., Brunovský, M., Stopková, P., & Höschl, C. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0506-8 · Cited by 42
“) as was discussed in previous studies [4, 46].”
ResultFishbain, D. A., Cole, B., Lewis, J. E., & Gao, J. (2014) · Pain Medicine · doi:10.1111/pme.12448 · Cited by 47
Panaite, V., Hindash, A. C., Bylsma, L. M., Small, B. J., Salomon, K., & Rottenberg, J. A. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2015.12.002 · Cited by 46
Lin, C., Chen, M., Yang, W., & Lane, H.-Y. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.019 · Cited by 43
“…(2015 course of acute treatment (mostly at week 1 or 2) for patients with major psychiatric disorders (Correll et al., 2013; Henkel et al., 2009; Kemp et al., 2011a, 2011b; Leucht et al., 2008; Machado-Vieira et al., 2013; O'Gorman et al., 2011; Szegedi et al., 2009, 2003; Vermeiden et al., 2015).”
BackgroundNakajima, S., Uchida, H., Suzuki, T., Watanabe, K., Hirano, J., Yagihashi, T., Takeuchi, H., Abe, T., Kashima, H., & Mimura, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.08.008 · Cited by 40
Han, C., Wang, S., Kwak, K., Won, W.-Y., Lee, H.-Y., Chang, C., Tang, T. C., & Pae, C. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.020 · Cited by 41
Combination antidepressant therapy for major depressive disorder: Speed and probability of remission
Stewart, J. W., McGrath, P. J., Blondeau, C., Deliyannides, D. A., Hellerstein, D. J., Norris, S., Amat, J., Pilowsky, D. J., Tessier, P., Laberge, L., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.12.001 · Cited by 50
Early response to antidepressant treatment in bulimia nervosa
Sysko, R., Sha, N., Wang, Y., Duan, N., & Walsh, B. T. (2009) · Psychological Medicine · doi:10.1017/s0033291709991218 · Cited by 39
“…f Cambridge University Press 2009 doi:10.1017/S0033291709991218 ORIGINAL ARTICLE response can be useful in predicting treatment outcome (e.g. Grilo & Masheb, 2007 ; Masheb & Grilo, 2007 ; Kinon et al. 2008 ; le Grange et al. 2008 ; Pollack et al. 2008 ; Szegedi et al. 2009 ; Tao et al. 2009).”
BackgroundInfluentialNoma, H., Furukawa, T. A., Maruo, K., Imai, H., Shinohara, K., Tanaka, S., Ikeda, K., Yamawaki, S., & Cipriani, A. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.031 · Cited by 36
“The early response was defined as more than 20% reduction of HRSD score within two weeks from the start of the trials (Szegedi et al., 2009).”
de la Salle, S., Phillips, J. L., Blier, P., & Knott, V. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110507 · Cited by 38
Lin, C., Park, C., & McIntyre, R. S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.082 · Cited by 37
Yuan, H., Zhu, X. L., Tang, W., Cai, Y., Shi, S., & Luo, Q. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.041 · Cited by 33
Clinical features and drug induced side effects in early versus late antidepressant responders
Fabbri, C., Marsano, A., Balestri, M., Ronchi, D. D., & Serretti, A. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.05.020 · Cited by 35
“Consistently, improvement atweek 2was found a sensitive predictor of subsequent response in a largemeta-analysis (Szegedi et al., 2009) and it was recently demonstrated that early switching vs continuation inearlynonrespondersmayprovideabetteroutcome(Nakajima et al.”
BackgroundAn algorithm for the pharmacological treatment of depression
Spijker, J., & Nolen, W. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01492.x · Cited by 35
“There is some general consensus to wait for at least 4 weeks (with an adequate dosage) (27), with the option to extend the trial to 6 weeks in case of some improvement (partial response) at week 4 (28) or to 10 weeks in case of combination treatment with psychotherapy (9).”
BackgroundDepression in the Primary Care Setting
Ellis, P., Kitay, B. M., & Schmidt, C. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1903259 · Cited by 34
Kudlow, P. A., Cha, D. S., & McLntyre, R. S. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205701211 · Cited by 32
Hoexter, M. Q., Diniz, J. B., Lopes, A. C., Batistuzzo, M. C., Shavitt, R. G., Dougherty, D. D., Duran, F., Bressan, R. A., Busatto, G. F., Miguel, E. C., et al. (2015) · Depression and Anxiety · doi:10.1002/da.22380 · Cited by 37
“[4] Given such limited effectiveness, the baseline identification of treatment response to first-line strategies is a desirable goal in OCD as delayed treatment has been associated with a worse prognosis.[5, 6] Therefore, being able to predict which individual patients are most likely to benefit from specific treatmen…”
BackgroundCosta, D. L. D. C., Shavitt, R. G., Cesar, R. C., Joaquim, M. A., Borcato, S., Valério, C., Miguel, E. C., & Diniz, J. B. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.07.006 · Cited by 36
“Our results resemble previous findings from most studies that have investigated the effect of SSRI on the outcome of depression (Henkel et al., 2009; Johansson and Jansson, 2010; Kemp et al., 2011; Szegedi et al., 2009; Tadi c et al., 2010).”
BackgroundResultBotulinum Toxin as a Treatment for Depression in a Real-world Setting
CHUGH, S., Chhabria, A., Jung, S., Krüger, T. H. C., & Wollmer, M. A. (2018) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000277 · Cited by 39
Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 report
Sajjadian, M., Uher, R., Ho, K. T., Hassel, S., Milev, R. V., Frey, B. N., Farzan, F., Blier, P., Foster, J. A., Parikh, S. V., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291722002124 · Cited by 38
“Response to antidepressants evolves over 6 – 8 weeks, but early changes in symptoms within the first 2 weeks of treatment are predictive of longer-term outcomes (Szegedi et al., 2009).”
Predicting antidepressant response using early changes in cognition: A systematic review
Park, C., Pan, Z., Brietzke, E. M., Subramaniapillai, M., Rosenblat, J. D., Zuckerman, H., Lee, Y. L., Fus, D., & McIntyre, R. S. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.07.011 · Cited by 47
Tadić, A., Wagner, S., Gorbulev, S., Dahmen, N., Hiemke, C., Braus, D. F., & Lieb, K. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-16 · Cited by 33
Early Prediction of Fluoxetine Response for Han Chinese Inpatients With Major Depressive Disorder
Lin, C., Lane, H., Chen, C., Juo, S. H., & Yen, C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318210856f · Cited by 32
Wang, L.-J., Kuang, W.-H., Xu, J.-J., Lei, D., & Yang, Y.-C. (2014) · Journal of International Medical Research · doi:10.1177/0300060514533524 · Cited by 31
Gorwood, P. A. P. M., Bayle, F., Vaïva, G., Courtet, P., Corruble, E., & Llorca, P. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2012.11.004 · Cited by 31
“Eleven studies [4,5,16,23,31,32,45,48,49,53,54], plus the present one, analyzed the effect of early improvement to predict later response in major depressive disorder, and were thus eligible for a meta-analysis (Table 4).”
BackgroundResultInfluentialRational site-directed pharmacotherapy for major depressive disorder
Blier, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000400 · Cited by 29
“When a monotherapy is implemented, if there is not a 20% improvement after 2 wk, the likelihood of achieving remission by the end of the trial is about 4% (Szegedi et al., 2009).”
BackgroundSchwartzmann, B., Quilty, L. C., Dhami, P., Uher, R., Allen, T. A., Kloiber, S. M., Lam, R. W. M., Frey, B. N., Milev, R. V., Müller, D. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35179-4 · Cited by 44
Shen, T., Li, X., Chen, L., Chen, Z., Tan, T., Hua, T., Chen, B., Yuan, Y., Zhang, Z., Kuney, L., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.111 · Cited by 40
Engelmann, J., Zillich, L., Frank, J., Wagner, S., Cetin, M., Herzog, D. P., Müller, M. B., Tadic, A., Foo, J. C., Sirignano, L., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02032-7 · Cited by 29
Mirman, A. M., Corlier, J., Wilson, A. C., Tadayonnejad, R., Marder, K. G., Pleman, C. M., Krantz, D. E., Wilke, S. A., Levitt, J. G., Ginder, N. D., et al. (2022) · Depression and Anxiety · doi:10.1002/da.23237 · Cited by 30
“Predicting outcome with an early response is well‐ documented in the literature for antidepressant medication, psychotherapy, ECT, and rTMS (Lin et al., 2016; Schlagert & Hiller, 2017; Szegedi et al., 2009; van Calker et al., 2009).”
Backgroundthe EMC Study Group, Tadić, A., Gorbulev, S., Dahmen, N., Hiemke, C., Braus, D. F., Röschke, J., van Calker, D., Wachtlin, D., Kronfeld, K., et al. (2010) · Trials · doi:10.1186/1745-6215-11-21 · Cited by 29
Lam, R. W., Endicott, J., Hsu, M.-A., Fayyad, R., Guico-Pabia, C., & Boucher, M. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000031 · Cited by 28
“Symptomatic improvement during the first few weeks of treatment has been shown to predict later response or remission with some antidepressants (Szegedi et al., 2003, 2009; Kok et al., 2009; Soares et al., 2014) and may also be predictive of improvements in functioning.”
Schneider, E. M., Linden, M., Weigmann, H., Wagner, T., Quail, D., Hundemer, H., & Hegerl, U. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-150 · Cited by 28
Vilazodone in the treatment of major depressive disorder
Khan, A., Sambunaris, A., Edwards, J. G., Ruth, A., & Robinson, D. S. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000016 · Cited by 29
“Early improvement (e.g. within 2 weeks) may enhance treatment compliance and lessen relapse or recurrence (Demyttenaere et al., 2001; Taylor et al., 2006; Szegedi et al., 2009).”
BackgroundBallenger, J. C. (2011) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(10)79300-2 · Cited by 28
Hellerstein, D. J., & Flaxer, J. M. (2015) · Core evidence · doi:10.2147/ce.s54075 · Cited by 30
“However, even the strongest proponents of the early onset of antidepressant action do not suggest that drug-induced early remissions are likely”.(53) Data for vilazodone(50) demonstrate low rates of remission at week 1 (0.”
Metadata
- Authors
- Szegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E.
- Affiliations
- University of Pennsylvania (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-02-24
- Volume
- 70
- Issue
- 3
- Pages
- 344-353
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2132699864
- Cited by
- 341
- References
- 0
- Citations by year
- 2026: 22 · 2025: 11 · 2024: 17 · 2023: 25 · 2022: 23 · 2021: 18 · 2020: 13 · 2019: 23 · 2018: 14 · 2017: 20 · 2016: 20 · 2015: 23 · 2014: 14 · 2013: 25 · 2012: 24
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- major depressive disorder, mirtazapine, early treatment response, treatment outcome prediction, antidepressant response, remission, rapid titration, dose titration, Hamilton Depression Rating Scale, predictive validity, negative predictive value, positive predictive value, sensitivity and specificity, antidepressant trials, inpatients and outpatients, treatment-resistant depression
- MeSH terms
- Mirtazapine, Antidepressive Agents, Clinical Trials as Topic, Major Depressive Disorder, Humans, Mianserin, Personality Inventory, Prognosis, Time Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.